STAT+: Pharmalittle: Wegovy cuts heart attack risk in milestone trial; AstraZeneca prioritizes U.S. for RSV drug amid surge
Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark trial, affirming it offers health benefits beyond weight loss.
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online calls, meetings, and deadlines has predictably returned.
